Pancreatic cancer patients across stages who were categorized as DDR-deficient based on the presence of germline or somatic mutations in BRCA1/BRCA2 or other DDR gene mutations had better median OS than DDR-proficient patients when exposed to platinums but not if platinum drugs were not part of their treatment [47]. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.